28356949|t|Association between XRCC1 and ERCC1 single-nucleotide polymorphisms and the efficacy of concurrent radiochemotherapy in patients with esophageal squamous cell carcinoma
28356949|a|The aim of the present study was to investigate the association between single-nucleotide polymorphisms (SNPs) in X-ray repair cross-complementing 1-399 (XRCC1-399) or excision repair cross-complementation group 1-118 (ERCC1-118) and the short-term efficacy of radiochemotherapy, tumor metastasis and relapse, as well as the survival time in patients with esophageal squamous cell carcinoma (ESCC). TaqMan probe-based quantitative polymerase chain reaction (qPCR) was conducted to examine the levels of XRCC1-399 and ERCC1-118 SNPs in the peripheral blood of 50 patients with pathologically confirmed ESCC. In addition, the associations between different genotypes and short-term therapeutic efficacy [the complete remission (CR) rate], tumor metastasis and relapse, as well as the survival time following concurrent radiochemotherapy, were determined. A total of 50 ESCC patients who received concurrent radiochemotherapy were enrolled. It was found that the short-term therapeutic efficacy (CR rate) was higher in the group of patients carrying the homozygous mutation of XRCC1-399 (A / A genotype) than in the group of patients without the XRCC1-399 mutation (G / G genotype). In addition, the CR rate was significantly increased in patients carrying one or two ERCC1-118 C alleles (C / C or C / T genotype) compared with patients lacking the C allele (T / T genotype). The differences were statistically significant (A / A vs. G / G, P=0.014; T T vs. C / T + C / C, P=0.040). During the follow-up period, the group of patients carrying the homozygous mutation of XRCC1-399 (A / A genotype) exhibited a markedly reduced risk of metastasis and relapse compared with the group of patients carrying non-mutated XRCC1-399 (G / G genotype; P=0.031). By contrast, ERCC1-118 SNP was not associated with the risk of metastasis and recurrence (P>0.05). The combined results of univariate and multivariate Cox regression analysis showed that the SNP in ERCC1-118 was closely associated with survival time. The mean survival time was significantly prolonged in patients carrying 1 or 2 C alleles (C / C or C / T genotype) compared with patients lacking the C allele (T / T genotype) [T / T vs. C / C, HR =12.96, 95% confidence interval (CI)=3.08-54.61, P<0.001; T T vs. C / T + C / C, HR =11.71, 95% CI =3.06-44.83, P<0.001]. However, XRCC1-399 SNP had no effect on survival time (P>0.05). XRCCl-399 SNP was associated with the short-term therapeutic efficacy (the CR rate) and tumor metastasis / relapse in ESCC patients who received the docetaxel plus cisplatin (TP) regimen -based concurrent radiochemotherapy. By contrast, ERCC1-118 SNP was significantly associated with the short-term therapeutic efficacy (the CR rate) and survival time in ESCC patients who received TP regimen -based concurrent radiochemotherapy.
28356949	20	25	XRCC1	T017	UMLS:C1366475
28356949	30	35	ERCC1	T017	UMLS:C1333355
28356949	36	67	single-nucleotide polymorphisms	T082	UMLS:C0752046
28356949	88	116	concurrent radiochemotherapy	T058	UMLS:C3178775
28356949	134	168	esophageal squamous cell carcinoma	T038	UMLS:C0279626
28356949	241	272	single-nucleotide polymorphisms	T082	UMLS:C0752046
28356949	274	278	SNPs	T082	UMLS:C0752046
28356949	283	321	X-ray repair cross-complementing 1-399	T017	UMLS:C1366475
28356949	323	332	XRCC1-399	T017	UMLS:C1366475
28356949	337	386	excision repair cross-complementation group 1-118	T017	UMLS:C1333355
28356949	388	397	ERCC1-118	T017	UMLS:C1333355
28356949	430	447	radiochemotherapy	T058	UMLS:C0436307
28356949	449	465	tumor metastasis	T038	UMLS:C0027627
28356949	494	507	survival time	T201	UMLS:C2919552
28356949	525	559	esophageal squamous cell carcinoma	T038	UMLS:C0279626
28356949	561	565	ESCC	T038	UMLS:C0279626
28356949	568	625	TaqMan probe-based quantitative polymerase chain reaction	T062	UMLS:C3179034
28356949	627	631	qPCR	T062	UMLS:C3179034
28356949	650	657	examine	T033	UMLS:C0332128
28356949	672	681	XRCC1-399	T017	UMLS:C1366475
28356949	686	695	ERCC1-118	T017	UMLS:C1333355
28356949	696	700	SNPs	T082	UMLS:C0752046
28356949	708	724	peripheral blood	T031	UMLS:C0229664
28356949	760	769	confirmed	T033	UMLS:C0750484
28356949	770	774	ESCC	T038	UMLS:C0279626
28356949	875	893	complete remission	T033	UMLS:C0677874
28356949	895	897	CR	T033	UMLS:C0677874
28356949	906	922	tumor metastasis	T038	UMLS:C0027627
28356949	951	964	survival time	T201	UMLS:C2919552
28356949	975	1003	concurrent radiochemotherapy	T058	UMLS:C3178775
28356949	1036	1040	ESCC	T038	UMLS:C0279626
28356949	1063	1091	concurrent radiochemotherapy	T058	UMLS:C3178775
28356949	1162	1164	CR	T033	UMLS:C0677874
28356949	1220	1239	homozygous mutation	T038	UMLS:C0026882
28356949	1243	1252	XRCC1-399	T017	UMLS:C1366475
28356949	1254	1255	A	T103	UMLS:C0001443
28356949	1258	1259	A	T103	UMLS:C0001443
28356949	1312	1321	XRCC1-399	T017	UMLS:C1366475
28356949	1322	1330	mutation	T038	UMLS:C0026882
28356949	1332	1333	G	T103	UMLS:C0018330
28356949	1336	1337	G	T103	UMLS:C0018330
28356949	1366	1368	CR	T033	UMLS:C0677874
28356949	1434	1443	ERCC1-118	T017	UMLS:C1333355
28356949	1446	1453	alleles	T017	UMLS:C0002085
28356949	1455	1456	C	T103	UMLS:C0010715
28356949	1459	1460	C	T103	UMLS:C0010715
28356949	1464	1465	C	T103	UMLS:C0010715
28356949	1468	1469	T	T103	UMLS:C0040077
28356949	1515	1516	C	T103	UMLS:C0010715
28356949	1517	1523	allele	T017	UMLS:C0002085
28356949	1525	1526	T	T103	UMLS:C0040077
28356949	1529	1530	T	T103	UMLS:C0040077
28356949	1590	1591	A	T103	UMLS:C0001443
28356949	1594	1595	A	T103	UMLS:C0001443
28356949	1600	1601	G	T103	UMLS:C0018330
28356949	1604	1605	G	T103	UMLS:C0018330
28356949	1616	1617	T	T103	UMLS:C0040077
28356949	1618	1619	T	T103	UMLS:C0040077
28356949	1624	1625	C	T103	UMLS:C0010715
28356949	1628	1629	T	T103	UMLS:C0040077
28356949	1632	1633	C	T103	UMLS:C0010715
28356949	1636	1637	C	T103	UMLS:C0010715
28356949	1660	1676	follow-up period	T033	UMLS:C0589120
28356949	1713	1732	homozygous mutation	T038	UMLS:C0026882
28356949	1736	1745	XRCC1-399	T017	UMLS:C1366475
28356949	1747	1748	A	T103	UMLS:C0001443
28356949	1751	1752	A	T103	UMLS:C0001443
28356949	1800	1810	metastasis	T038	UMLS:C4255448
28356949	1880	1889	XRCC1-399	T017	UMLS:C1366475
28356949	1891	1892	G	T103	UMLS:C0018330
28356949	1895	1896	G	T103	UMLS:C0018330
28356949	1930	1939	ERCC1-118	T017	UMLS:C1333355
28356949	1940	1943	SNP	T082	UMLS:C0752046
28356949	1980	1990	metastasis	T038	UMLS:C4255448
28356949	2055	2091	multivariate Cox regression analysis	T170	UMLS:C0034980
28356949	2108	2111	SNP	T082	UMLS:C0752046
28356949	2115	2124	ERCC1-118	T017	UMLS:C1333355
28356949	2153	2166	survival time	T201	UMLS:C2919552
28356949	2247	2248	C	T103	UMLS:C0010715
28356949	2249	2256	alleles	T017	UMLS:C0002085
28356949	2258	2259	C	T103	UMLS:C0010715
28356949	2262	2263	C	T103	UMLS:C0010715
28356949	2267	2268	C	T103	UMLS:C0010715
28356949	2271	2272	T	T103	UMLS:C0040077
28356949	2318	2319	C	T103	UMLS:C0010715
28356949	2320	2326	allele	T017	UMLS:C0002085
28356949	2328	2329	T	T103	UMLS:C0040077
28356949	2332	2333	T	T103	UMLS:C0040077
28356949	2345	2346	T	T103	UMLS:C0040077
28356949	2349	2350	T	T103	UMLS:C0040077
28356949	2355	2356	C	T103	UMLS:C0010715
28356949	2359	2360	C	T103	UMLS:C0010715
28356949	2423	2424	T	T103	UMLS:C0040077
28356949	2425	2426	T	T103	UMLS:C0040077
28356949	2431	2432	C	T103	UMLS:C0010715
28356949	2435	2436	T	T103	UMLS:C0040077
28356949	2439	2440	C	T103	UMLS:C0010715
28356949	2443	2444	C	T103	UMLS:C0010715
28356949	2496	2505	XRCC1-399	T017	UMLS:C1366475
28356949	2506	2509	SNP	T082	UMLS:C0752046
28356949	2527	2540	survival time	T201	UMLS:C2919552
28356949	2551	2560	XRCCl-399	T017	UMLS:C1366475
28356949	2561	2564	SNP	T082	UMLS:C0752046
28356949	2626	2628	CR	T033	UMLS:C0677874
28356949	2639	2655	tumor metastasis	T038	UMLS:C0027627
28356949	2669	2673	ESCC	T038	UMLS:C0279626
28356949	2700	2737	docetaxel plus cisplatin (TP) regimen	T058	UMLS:C1880380
28356949	2745	2773	concurrent radiochemotherapy	T058	UMLS:C3178775
28356949	2788	2797	ERCC1-118	T017	UMLS:C1333355
28356949	2798	2801	SNP	T082	UMLS:C0752046
28356949	2877	2879	CR	T033	UMLS:C0677874
28356949	2890	2903	survival time	T201	UMLS:C2919552
28356949	2907	2911	ESCC	T038	UMLS:C0279626
28356949	2934	2944	TP regimen	T058	UMLS:C1880380
28356949	2952	2980	concurrent radiochemotherapy	T058	UMLS:C3178775